risperidone has been researched along with pergolide in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (12.50) | 18.2507 |
2000's | 4 (50.00) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Ahman, M; Holmén, AG; Wan, H | 1 |
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
Sen, S; Sinha, N | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Brooks, D; Evans, SM; Levin, FR; McDowell, D; Nunes, EV; Spano, C | 1 |
Kesler, S; Niehaus, DJ; Seedat, S; Stein, DJ | 1 |
Baran, AS; Rack, MJ; Richert, AC; Roffwarg, HP | 1 |
1 review(s) available for risperidone and pergolide
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for risperidone and pergolide
Article | Year |
---|---|
Pergolide mesylate for cocaine abuse: a controlled preliminary trial.
Topics: Adult; Cocaine-Related Disorders; Dopamine Agonists; Dopamine Antagonists; Double-Blind Method; Female; Humans; Male; Pergolide; Psychiatric Status Rating Scales; Risperidone; Single-Blind Method; Time Factors; Treatment Outcome | 1999 |
6 other study(ies) available for risperidone and pergolide
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents.
Topics: Antipsychotic Agents; Carbidopa; Dopamine Agonists; Drug Therapy, Combination; Female; Gambling; Humans; Impulsive Behavior; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Risperidone; Treatment Outcome | 2000 |
Cardiopulmonary complications of ergot-derivative dopamine agonists.
Topics: Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Pergolide; Pulmonary Fibrosis; Risperidone | 2004 |